Committed to shaping the future of surgery in the fight against obesity and metabolic diseases and helping to elevate the standard of care through research and evidence, best-in-class education and training, innovative products and expanding patient access to care. Together, we’re advancing surgical care, enabling patients to live longer, more fulfilling lives.
Ethicon Bariatric Solutions
Innovation in the operating room. Ethicon offers a comprehensive portfolio of medical device products for bariatric and metabolic surgery. We relentlessly invest in innovation to provide a comprehensive portfolio of market-leading products.
Your Choice of Stapler Matters
With decisions ranging from surgical approach to post-operative management, every choice matters. One choice you can count on is Ethicon Powered Staplers. We focus on providing you staplers that help improve patient outcomes, with results backed by clinical evidence.
Bariatric Professional Education Courses
The Johnson & Johnson Institute offers comprehensive Bariatric specialty learning opportunities on the safe and efficacious usage of Ethicon devices, surgical techniques and measures to provide ongoing learning opportunities to improve patient outcomes.
Orthopaedic Coordinated Care Program
Enabling options for patients with severe obesity who are denied access to total joint procedures based on BMI and related risk factors. The need for total knee arthroplasty is 8.5X higher in patients with a BMI over 30 and 32X in patients with a BMI over 40 than patients in a normal weight category.1
HealthPartner for Weight Loss Surgery
A comprehensive digital support solution to guide patients throughout the bariatric surgery journey
HealthPartner for Weight Loss Surgery supports your patients through the entire bariatric surgery journey. The website and app help to educate patients, guide them through the pre-surgical process, support them in behavior change goal setting, and allow them to track their progress.
ECHELON FLEX™ GST System
ECHELON FLEX™: Bariatric surgeons prefer Ethicon endocutters more often than Medtronic endocutters.§
Controls tissue movement to enable you to transect as you intend even in challenging tissue.
Uniquely designed for the most precise transection, with a better grip// to provide the least tissue slippage¶. Provides exceptional staple line integrity across the broadest range of tissue thicknesses compared to Medtronic TriStaple™ portfolioΩII.
HARMONIC ACE®+7 SHEARS with Advanced Hemostasis
Uniting the precision and multifunctionality of HARMONIC® Shears with strong, secure vessel sealing
Provides superior heat management2,3
Adaptive Tissue Technology enables greater surgical precision and performance4 by dynamically optimizing energy delivery in response to changing tissue conditions.
STRATAFIX™ Spiral Knotless Tissue Control Device
Delivering more security, consistency, and efficiency$5-13
With more points of fixation than traditional sutures. STRATAFIX™ Devices provide more consistent tension control over every pass and provides more security and strength than interrupted suture closure with more efficiency than continuous closure.6,7,10
PROXISURE™ Suturing Device
PROXISURE™ enables precise suturing in tight spaces, which may lead to reduced OR time and cost.14-24
PROXISURE™ offers bidirectional 45-degree articulation and 360-degree rotation25 at the distal end. PROXISURE™ has a curved needle that improves a surgeon’s ability to suture a variety of tissue types, including flat surfaces. PROXISURE™ enables surgeons to easily tie intracorporeal knots.26
Ethicon Bariatric Resources
Ethicon provides highly demanded assets through this digital platform all at no charge & can be viewed online before ordering.
As potential patients learn about bariatric and metabolic surgery, they also search for surgeons in their area.
Research & evidence
Driving the body of evidence that shows bariatric surgery is the most effective and durable treatment for severe obesity.
* Use of Ethicon powered staplers was associated with fewer bleeding / transfusion complications (1.61%) compared to Medtronic non-powered staplers (3.05%) p=0.010, in laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass procedures. Based on retrospective analysis of 21,466 cases from the Premier Perspective® Hospital Database.
† Use of Ethicon powered staplers was associated with shorter OR time (133 minutes) compared to Medtronic non-powered staplers (154 minutes), p=0.011, in laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass procedures. Based on retrospective analysis of 20,428 cases from the Premier Perspective® Hospital Database.
‡ Use of Ethicon powered staplers was associated with lower overall hospital costs ($12,261) compared to Medtronic non-powered staplers ($14,038), p=0.022, in laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass procedures. Based on retrospective analysis of 21,466 cases from the Premier Perspective® Hospital Database. (065629-170118)
§ In a 2015 U.S. market research study by Ethicon that surveyed surgeon preference (63.9% Ethicon vs. 24.7% Medtronic) (p<0.001).
// Benchtop testing in porcine stomach tissue. Tissue grasping force of ECHELON FLEX™ GST System vs Tri-Staple™ (GST60B 6.496lbf & GST60T 7.789lbf vs EGIA60AMT 1.325lbf & EGIA60AXT 1.920lbf, all p<0.001). Based on similar design features between 45mm and 60mm end effectors, no significant difference in performance is expected between the 45mm & 60mm devices of each brand.
¶ Benchtop testing in porcine stomach tissue. Mean tissue movement from after clamping on tissue to after firing ECHELON FLEX™ Powered Plus Stapler (PSEE60A) and ECHELON Reload with GST vs ENDO GIA™ ULTRA Handle (EGIAUSTND) and Endo GIA™ Reload with Tri-Staple™ Technology at 1.5, 2.5, 3.3 and 4.0mm tissue thicknesses (1.5mm: GST60B 1.067mm vs EGIA60AMT 2.452mm p<0.001; 2.5mm: GST60G 1.148mm vs EGIA60AMT 3.261mm p<0.001; 3.3mm: GST60T 0.642mm vs EGIA60AMT 4.806mm p<0.001; 4.0mm: GST60T 0.654mm vs EGIA60AXT 5.116mm p<0.001).
Ω The ECHELON FLEX™ GST System was designed and tested to meet rigorous design requirements for staple line integrity. The GST System accommodates a tissue thickness range of 1.0mm to 4.0mm (measured at 8g/mm2, tissue comfortably compressed to closed staple height during firing per IFU) while the Medtronic Tri-Staple™ portfolio is intended for a tissue thickness range of 0.75mm to 3.0mm (per IFU & materials downloaded from Medtronic website on Nov 16, 2016).
II Comparison of the ECHELON FLEX™ GST System designed to accommodate a tissue thickness range of 1.0mm to 4.0mm (as measured with an 8g/mm2 tissue measuring device) vs the Medtronic Tri-Staple portfolio intended for a thickness range of 0.75mm to 3.0mm (Medtronic literature, downloaded from Medtronic website on Nov 16, 2016)
$ Than traditional sutures
1. Bartsch E, Nuzzo C, Alsford J, et al. Sustainable Economics: the Bitter Aftertaste of Sugar. Morgan Stanley Research.18 March 2015.
2. In a benchtop study on porcine jejunum, ThunderbeatTM (Seal and Cut mode) exhibited 31.7% higher mean shaft temperature (Fahrenheit) on the last 3 of 20 transections vs. Ethicon ACE® Devices with Adaptive Tissue Technology at Max Power Level 5 (p<0.001).
3. In a preclinical study on 5-7mm goat carotids (n=76) that compared the mean thermal damage via histology of HARMONIC ACE®+7 in Advanced Hemostasis mode vs LigaSureTM Blunt Tip (LF1537) (2 54 [±0.48] mm. respectively, p=0.003).
4. As compared to HARMONIC® Devices without Adaptive Tissue Technology
5. Moran ME, Marsh C, Perrotti M. Bidirectional-barbed sutured knotless running anastomosis v classic Van Velthoven suturing in a model system. J Endourol. 2007;21(10):1175-1178.
6. Vakil JJ, O'Reilly MP, Sutter EG, Mears SC, Belkoff SM, Khanuja HS. Knee arthrotomy repair with a continuous barbed suture: a biomechanical study. J Arthroplasty. 2011;26(5):710-713.
7. Eickmann T, Quane E. Total knee arthroplasty closure with barbed sutures. J Knee Surg. 2010;23(3):163-167.
8. Einarsson JI, Chavan NR, Suzuki Y, Jonsdottir G, Vellinga TT, Greenberg JA. Use of bidirectional barbed suture in laparoscopic myomectomy: evaluation of perioperative outcomes, safety, and efficacy. J Minim Invasive Gynecol. 2011;18(1):92-95.
9. Levine BR, Ting N, Della Valle CJ. Use of a barbed suture in the closure of hip and knee arthroplasty wounds. Orthopedics. 2011;34(9):e473-e475. doi:10.3928/01477447-20110714-35.
10. 100326296: Time Zero Tissue Holding - Competitive Claims Comparisons for STRATAFIX Knotless Tissue Control Devices vs Various Products. 2015.
11. AST-2012-0331. Tissue gapping under tension of porcine cadaveric skin incisions closed with Stratafix Spiral in comparison to Monocryl in both interrupted and continuous stitching patterns. Approved on August 24, 2012. Performance Testing of STRATAFIX SYMMETRIC PDS PLUS Size 0 & 1 Devices – Initiation Strength in Porcine Tissue. AST-2013-0603.
12. Ethicon Performance Evaluation Memo AST-2012-0510. Performance Testing of STRATAFIX Symmetric Size 2-0 suture device for Tissue Holding Strength with an Incision Defect to Measure Gapping. Dated December 3, 2012.
13. AST-2013-0056 Performance Testing of STRATAFIX Symmetric PDSSize2-0 suture device for Tissue Holding Strength with Multiple Incision Defects to Measure Gapping.
14. KosydarA_20160302_Design Science_Project Stitch Full Study_DOF_TR_20160302.pdf
15. ArnoldB_PRC075746_Ethicon_ProxiSure Suturing Device_DOF_BENCH_20160523.pdf
18. PATTARAS_2001_JOURNAL OF ENDOUROLOGY_15_187 .pdf Hart_2013_JSLS_17_508.pdf
24. ArnoldB_PRC075746_Ethicon_ProxiSure Suturing Device_DOF_BENCH_20160523.pdf
25. PROXISURE™ Suturing Device Instructions For Use.
26. Evaluation of physical and functional properties of size 2-0 Ethicon VICRYL Plus, Syneture Polysorb and B Braun Novosyn suture. AST-2013-0261. 2013.
EVICEL® Fibrin Sealant (Human) IMPORTANT SAFETY INFORMATION
EVICEL® Fibrin Sealant (Human) is indicated as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical.
- Do not inject directly into the circulatory system. Intravascular application of EVICEL® may result in life-threatening thromboembolic events.
- Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products.
- Do not use for the treatment of severe or brisk arterial bleeding.
- Do not use EVICEL® for spraying in endoscopic or laparoscopic procedures where the minimum recommended distance from the applicator tip to the target site cannot be ensured.
Warnings and Precautions
- Life-threatening air or gas embolism has occurred with the use of spray devices employing a pressure regulator to administer EVICEL®. This event appears to be related to the use of the spray device at pressures higher than recommended and/or at distances closer than recommended to the surface of the tissue.
- Monitor changes in blood pressure, pulse, oxygen saturation, and end-tidal CO2 when spraying EVICEL® because of the possibility of gas embolism.
- To reduce the risk of potentially life-threatening gas embolism, spray EVICEL® using only pressurized CO2 gas at the pressures and distances recommended for the specific tips.
- Use EVICEL® spray application only if it is possible to accurately judge the spray distance, especially during endoscopic or laparoscopic procedures.
- Prior to applying EVICEL®, dry surface areas of the wound by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices). Prepare and administer EVICEL® according to the instructions and with only devices recommended for this product.
- May carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The most common adverse reactions reported in clinical trials are peripheral edema, abdominal abscess, infection, hematoma, incision site hemorrhage, vascular graft occlusion, postoperative wound complication and decreased hemoglobin.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
SURGICEL® Essential Product Information
SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is used adjunctively in surgical procedures to assist in the control of capillary, venous, and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective. SURGICEL® ORIGINAL, SURGICEL® FIBRILLAR™ and SURGICEL® NU-KNIT® Hemostats can be cut to size for use in endoscopic procedures.
- Use only as much SURGICEL® Absorbable Hemostat as is necessary for hemostasis, holding it firmly in place until bleeding stops. Remove any excess before surgical closure in order to facilitate absorption and minimize the possibility of foreign body reaction.
- In urological procedures, minimal amounts of SURGICEL® Absorbable Hemostat should be used and care must be exercised to prevent plugging of the urethra, ureter, or a catheter by dislodged portions of the product.
- Since absorption of SURGICEL® Absorbable Hemostat could be prevented in chemically cauterized areas, its use should not be preceded by application of silver nitrate or any other escharotic chemicals.
- If SURGICEL® Absorbable Hemostat is used temporarily to line the cavity of large open wounds, it should be placed so as not to overlap the skin edges. It should also be removed from open wounds by forceps or by irrigation with sterile water or saline solution after bleeding has stopped.
- Precautions should be taken in otorhinolaryngologic surgery to assure that none of the material is aspirated by the patient. (Examples: controlling hemorrhage after tonsillectomy and controlling epistaxis.)
- Care should be taken not to apply SURGICEL® Absorbable Hemostat too tightly when it is used as a wrap during vascular surgery (see Adverse Reactions).
- “Encapsulation” of fluid and foreign body reactions have been reported.
- There have been reports of stenotic effect when SURGICEL® Absorbable Hemostat has been applied as a wrap during vascular surgery.
- Paralysis and nerve damage have been reported when SURGICEL® Absorbable Hemostat was used around, in, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm.
- Blindness has been reported in connection with surgical repair of a lacerated left frontal lobe when SURGICEL® Absorbable Hemostat was placed in the anterior cranial fossa.
- Possible prolongation of drainage in cholecystectomies and difficulty passing urine per urethra after prostatectomy have been reported.
For more information, please consult your doctor or for product quality and technical questions, call 1-800-795-0012.